Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study.

Andersson H, Kirkhus E, Garen T, Walle-Hansen R, Merckoll E, Molberg Ø.

Arthritis Res Ther. 2017 Jan 25;19(1):17. doi: 10.1186/s13075-017-1219-y.

2.

Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy.

Elessawy SS, Abdelsalam EM, Abdel Razek E, Tharwat S.

Acta Radiol Open. 2016 Sep 21;5(9):2058460116668216.

3.

213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Benveniste O, Rider LG; ENMC Myositis Outcomes Study Group..

Neuromuscul Disord. 2016 Aug;26(8):523-34. doi: 10.1016/j.nmd.2016.05.014. No abstract available.

PMID:
27312023
4.

Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.

Loell I, Raouf J, Chen YW, Shi R, Nennesmo I, Alexanderson H, Dastmalchi M, Nagaraju K, Korotkova M, Lundberg IE.

Arthritis Res Ther. 2016 Jun 10;18(1):136. doi: 10.1186/s13075-016-1033-y.

5.

Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.

Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group..

Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753.

6.

Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.

Pandya JM, Loell I, Hossain MS, Zong M, Alexanderson H, Raghavan S, Lundberg IE, Malmström V.

Arthritis Res Ther. 2016 Apr 1;18:80. doi: 10.1186/s13075-016-0974-5.

7.

Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan.

Kawasumi H, Gono T, Kawaguchi Y, Kuwana M, Kaneko H, Katsumata Y, Kataoka S, Hanaoka M, Yamanaka H.

Biomed Res Int. 2016;2016:9163201. doi: 10.1155/2016/9163201.

8.

Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.

Campanilho-Marques R, Almeida B, Deakin C, Arnold K, Gallot N, de Iorio M, Nistala K, Pilkington CA, Wedderburn LR; Juvenile Dermatomyositis Research Group..

Arthritis Care Res (Hoboken). 2016 Oct;68(10):1514-21. doi: 10.1002/acr.22867.

9.

Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies.

van der Stap DK, Rider LG, Alexanderson H, Huber AM, Gualano B, Gordon P, van der Net J, Mathiesen P, Johnson LG, Ernste FC, Feldman BM, Houghton KM, Singh-Grewal D, Kutzbach AG, Alemo Munters L, Takken T; International Myositis Assessment and Clinical Studies Group..

J Rheumatol. 2016 Jan;43(1):169-76. doi: 10.3899/jrheum.150270. Review.

10.

Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.

Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O.

PLoS One. 2015 Nov 5;10(11):e0133702. doi: 10.1371/journal.pone.0133702.

11.

Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies.

Ge Y, Lu X, Peng Q, Shu X, Wang G.

PLoS One. 2015 Oct 28;10(10):e0141616. doi: 10.1371/journal.pone.0141616.

12.

Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.

Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, Miller FW, Rider LG.

Rheumatology (Oxford). 2016 Mar;55(3):441-9. doi: 10.1093/rheumatology/kev344.

13.

Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.

McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A, Appelbe D, Williamson PR, Beresford MW.

Trials. 2015 Jun 12;16:268. doi: 10.1186/s13063-015-0784-0.

14.

Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.

Iaccarino L, Pegoraro E, Bello L, Bettio S, Borella E, Nalotto L, Semplicini C, Sorarù G, Ghirardello A, Doria A.

Auto Immun Highlights. 2014 Oct 15;5(3):87-94. doi: 10.1007/s13317-014-0063-1. Review.

15.

Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.

Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Research Group..

Arthritis Rheumatol. 2015 Sep;67(9):2495-502. doi: 10.1002/art.39200.

16.

Wrist flexion and extension torques measured by highly sensitive dynamometer in healthy subjects from 5 to 80 years.

Decostre V, Canal A, Ollivier G, Ledoux I, Moraux A, Doppler V, Payan CA, Hogrel JY.

BMC Musculoskelet Disord. 2015 Jan 31;16:4. doi: 10.1186/s12891-015-0458-9.

17.

Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Rider LG, Dankó K, Miller FW.

Curr Opin Rheumatol. 2014 Nov;26(6):724-41. doi: 10.1097/BOR.0000000000000119. Review.

18.

Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.

Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):689-96.

19.

Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group., Oddis CV.

Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.

20.

Disease activity measures in paediatric rheumatic diseases.

Luca NJ, Feldman BM.

Int J Rheumatol. 2013;2013:715352. doi: 10.1155/2013/715352. Review.

Supplemental Content

Support Center